Bioventus Inc.
BVS
$6.55
$0.121.87%
NASDAQ
| 03/29/2025 | 12/31/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -4.31% | 13.45% | 15.04% | 10.32% | 8.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -4.31% | 13.45% | 15.04% | 10.32% | 8.73% |
| Cost of Revenue | -0.63% | 3.79% | 8.27% | -0.77% | -9.00% |
| Gross Profit | -6.02% | 18.95% | 18.64% | 16.29% | 19.56% |
| SG&A Expenses | -6.72% | 10.43% | 16.07% | 9.94% | -2.58% |
| Depreciation & Amortization | -9.23% | -15.89% | -10.88% | -10.03% | -17.57% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.29% | 7.29% | 13.01% | 5.78% | -5.81% |
| Operating Income | -4.79% | 330.66% | 79.50% | 78.22% | 140.68% |
| Income Before Tax | 37.58% | 102.76% | 41.01% | -806.92% | 94.53% |
| Income Tax Expenses | -110.47% | 173.33% | -1.83% | -2,026.25% | 721.23% |
| Earnings from Continuing Operations | 47.94% | 95.85% | 38.33% | -578.76% | 93.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -54.06% | -89.62% | -59.88% | 673.33% | -92.68% |
| Net Income | 46.07% | 97.44% | 33.94% | -551.78% | 96.49% |
| EBIT | -4.79% | 330.66% | 79.50% | 78.22% | 140.68% |
| EBITDA | -1.00% | 71.18% | 7.92% | 22.46% | 368.02% |
| EPS Basic | 48.32% | 97.52% | 36.40% | -536.90% | 96.55% |
| Normalized Basic EPS | 23.64% | 177.53% | 72.06% | 2,240.96% | -126.99% |
| EPS Diluted | 48.32% | 97.52% | 36.40% | -536.90% | 96.55% |
| Normalized Diluted EPS | 23.64% | 177.53% | 72.06% | 2,240.96% | -126.99% |
| Average Basic Shares Outstanding | 4.15% | 3.73% | 3.87% | 2.41% | 2.02% |
| Average Diluted Shares Outstanding | 4.15% | 3.73% | 3.87% | 2.41% | 2.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |